Jefferies Upgrades Edwards Lifesciences To Buy

According to Jefferies, Edwards Lifesciences EW is upgraded to Buy. Jefferies reported that, following the release of PARTNER Cohort A results and Cohort B economic benefit analysis, it is upgrading EW shares to Buy from Hold. “Based on the strong data and very positive clinician feedback, we are increasing TAVI penetration assumptions and our EW forecasts. We are increasing our price target to $103 (from $93).” Edwards Lifesciences closed on Friday at $86.07.